An observational study in Breast Cancer, Cancer Survivorship and Health Attitude, sponsored by Changi General Hospital. Recruiting at 1 site in Singapore. Open to female participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Changi General Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 200 studies in Breast Neoplasms with a site in Singapore — 35 open to participants now, 68 under way, 26 of them phase 3. Breast Neoplasms · Singapore.
Among the 200 studies in Breast Neoplasms with a site in Singapore, this one is the 9th largest by planned enrollment of the 24 observational ones that give a count, is one of 4 that started in 2026, is one of 31 observational ones, reaches primary completion later than 24 of the 67 other live ones, and was the 183rd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →35 of the 200 studies in Breast Neoplasms with a site in Singapore are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Singapore, United States, Canada and 6 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Singapore, United States, Canada and 8 more countries
Ages 18+
Eli Lilly and Company · Sites in Singapore, United States, Argentina and 16 more countries
Ages 18+
ALX Oncology Inc. · Sites in Singapore, United States, Canada and 5 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Singapore, United States, Canada and 4 more countries
Ages 18+
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 21 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
200 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 66 · Phase 3 60 · Phase 4 1
First in 1989; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 376 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 238 across the 166 interventional studies, 220 across the 24 observational. Of the 90 that completed or were terminated, 49 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 200 have an industry lead sponsor. The 10 most frequent:
Changi General Hospital is the lead sponsor of 101 studies on the registry; 18 are open to participants now.
Changi General Hospital has 2 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
22 of the studies in Breast Neoplasms with a site in Singapore that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT05696626Phase 3LeonaBioEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | 2027-04 |
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
| NCT05894239Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | 2027-05-03 |
| NCT06312176Phase 3Merck Sharp & Dohme LLCA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | 2027-07-11 |
Add all 22 to your calendar (.ics) → With an account.
Among the 200 studies in Breast Neoplasms with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators are attempting to verify the prevalence of cancer rehabilitation needs at our institution in breast cancer patients. The investigators also want to assess 1) self-perceived needs for cancer rehabilitation services, 2) awareness, willingness, and patient health beliefs as determinants for cancer rehabilitation-seeking behaviour, and 3) the modifiable patient factors driving the mismatch between needs and uptake in our population.
Patients attending outpatient clinics in our hospital will be approached to answer a questionnaire designed to find out this information. The investigators hope that the results will ultimately inform the design of better triage and referral systems that match patients to services based on their rehabilitation needs.
The investigators believe that local survivors of breast cancer have unmet rehabilitation needs and that it is possible to evaluate their readiness to seek access to rehabilitation services as well as identify mismatches between provided and desired services through the administration of a cancer rehabilitation questionnaire (CRQ).
STUDY DESIGN The study is conceptualised as a cross-sectional observational study of breast cancer survivors in a multiethnic urban Asian population that is representative of our demographic. It will conform to the STROBE guidelines. The study will be registered prior to site initiation. Ethics approval is pending.
STUDY POPULATION Consecutive purposive sample of all female patients with breast cancer in the Breast Surgery clinics (with Medical Oncology as a referring site).
CONDUCT OF STUDY The study will take place in the specialist outpatient clinics in CGH. All unique patients attending their clinic appointments will be screened. Patients fulfilling the inclusion and exclusion criteria will be approached for recruitment and enrolment. They will complete the questionnaire and provide relevant demographic features in the same sitting, within a private room. Verbal translation into Mandarin, Malay, or Tamil by the administrator will be done for patients who are unable to communicate in English. No audio or video recording will be performed.
CANCER REHABILITATION QUIESTIONNAIRE (EXPANDED) The Cancer Rehabilitation Questionnaire (CRQ) was designed by a team at the National University Hospital, Singapore, to investigate the functional problems faced by cancer survivors as well as their attitudes toward participation in rehabilitation. It comprises 12 common cancer-associated functional issues with yes/no answers, as well as further qualitative questions to explore barriers to participation in rehabilitation. The original tool was validated, with strong internal consistency and had a large effect size for differentiating clinically-significant declines in physical functioning. However, it was administered a decade ago and not optimised specifically for contemporary patients with breast cancer.
The investigators evaluated the components of the CRQ based on suitable available literature, and have expanded it with 2 more parts to reflect the increasing role of technology in healthcare delivery, allow patients to open-endedly discuss desired rehabilitation and therapy services, as well as explore concerns and health-seeking behaviours specific to breast cancer impairments and post-treatment sequelae.
STATISTICAL AND ANALYTIICAL PLANS Descriptive statistics of patient demographic and clinical characteristics will be reported as number and percent for categorical data, mean ± standard deviation (SD) for normally distributed data, and median and interquartile range (IQR) for non-normally distributed data. The prevalence of reported symptoms and impairments will be reported as number and percent of patients, with the corresponding 95% confidence intervals (CIs) of the population percentages.
Multivariable linear regression will be used to assess if reported impairments and impairment severity are independently associated with patients' self-assessed need for rehabilitative services. The linearity assumption will be assessed using the Box-Tidwell test, the homoscedasticity assumption using a plot of model residuals against fitted values, and the normality assumption using a quantile-quantile (Q-Q) plot. Cohen's Kappa (κ) will be used to examine agreement between patients' self-assessed need for rehabilitation and level of care needed, against physician-assessed needs and level of care required, as they are categorical variables.
Results for the questions pertaining to technology-enabled rehabilitation and barriers to rehabilitation will be reported through central tendency measures (mean ± SD or median + IQR, with 95% CIs). This is likewise for the Likert-type items that make up the Health Beliefs construct. Internal consistency of the health belief questions that evaluate the same concept will be assessed using Cronbach's alpha. Data will be tabulated and analysed using IBM SPSS Statistics version 26.0 (IBM Corp, Armonk, NY, USA). No interim analysis is necessary as the study is not conceptualised as a randomised controlled trial.
WITHDRAWAL FROM THE STUDY Subjects may withdraw voluntarily from participation in the study at any time, including after completion, with no prejudice to their clinical care or outpatient follow-up. Their data will be removed from the electronic records, and the hardcopy data collection form will be physically destroyed. Their withdrawal will be reported in the STROBE flowchart subsequently.
DISCONTINUATION OF THE STUDY The study may be discontinued for any of the following reasons.
SAFETY MONITORING PLAN Patients will be under the care of a trained study team member or CRC during recruitment and questionnaire administration. They will be monitored for discomfort during this period. Other clinical deteriorations will be managed routinely. Data will be reviewed on a monthly basis by an appointed co-investigator for integrity as well as completion. This includes screening and recruitment figures, as well as demographics, functional/clinical characteristics, as well as questionnaire responses. Data safety will be through lock-and-key storage of physical documents as well as access-restricted, password-protection for electronic data, which can only be viewed on the hospital's intranet-facing devices.
DATA ENTRY AND STORAGE Demographic data will be collected from patients' electronic medical records. Anthropometric and clinical measurements will be collected physically. All records will be recorded in a hardcopy data collection form to be filed in the Investigator Site File (ISF) that is stored under lock-and-key in the Research Office. All data will be transcribed electronically into REDCap which is hosted on the hospital's intranet and is access-restricted as well as password-protected. Only study team members (including the clinical research co-ordinator) will have access to the data. Data will be de-identified prior to analysis by the statistician. All data will be kept for 7 years post-completion or post-publication, whichever is later. Following that, electronic data will be deleted and all paper records will be physically destroyed.
DATA QUALITY ASSURANCE All data will be collected by a small pre-defined group of trained medical doctors and clinical research co-ordinators with medical backgrounds. All study team members will be pre-trained and briefed on the administration of the questionnaire. All data will be collected during the questionnaire administration, except for the Charlson Comorbidity Index which will require access to the patient's Electronic Medical Records (EMR). All study team members will have previous training and experience in accessing the patients' EMR.
ETHICAL CONSIDERATIONS This study will be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with the Good Clinical Practice and the applicable regulatory requirements. The principal investigator is responsible for informing the CIRB of any amendments to the protocol or other study-related documents, as per local requirement.
INFORMED CONSENT Informed consent will be collected prior to administration of a questionnaire. Patients will be screened upon registration in the respective clinics. Eligible patients would then be approached for consent while they are on-site. All study team members would be trained and hence eligible for consent-taking. Consent will be taken physically and in writing. Risks and benefits of participation will be clearly explained. Patients will be given ample time to make a decision and/or decline with no impact on their standard of clinical care. If a family member's presence is requested or deemed necessary but they cannot be present in the premises, the patient will not be recruited in that instance. The investigators will not consider remote consent as our target demographic is generally ambulant.
The requirement for a witness for all consent-taking is exempted as the study comprises solely of a survey under Regulation 26 of the Human Biomedical Research Regulations 2017 (not invasive, not interventional, not restricted human biomedical research). A legally-authorised representative (LAR) would not be required. Upon enrolment into the study, a note will be entered into the patient's electronic medical record. For non-English speakers, the investigators will use appropriate translation (in Mandarin, Malay, or Tamil) performed by the study team member or CRC. Patients with cognitive impairment meeting the diagnostic criteria for major neurocognitive disorder will not be recruited as this may affect the accuracy of their answers. The study team member assessing for cognitive impairment would have been satisfactorily trained prior. They will be treated as a vulnerable population and excluded from recruitment.
The investigators do not foresee the recruitment of other special populations such as children, prisoners, or other vulnerable individuals. In obtaining and documenting informed consent, the investigator should comply with the GCP guidelines and to the ethical principles that have their origin in the Declaration of Helsinki.
Consecutive purposive sample of all female patients with breast cancer in the Breast Surgery and Medical Oncology clinics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Female patients from the Breast Surgery clinic at Changi General Hospital (with referrals from the on-site Medical Oncology clinic). A consecutive purposive sample of 400 participants will be recruited. There are no race-based or minority-based subject restrictions. Male patients with breast cancer are rare and are thus excluded from recruitment. Patients will be approached by a clinical research co-ordinator (CRC) or study team member who will explain the study and seek consent for recruitment.
Symptom/impairment prevalence
The prevalence of reported symptoms and impairments among breast cancer survivors.
Time frame: At the point of recruitment
Awareness of available support
Awareness of available support for symptomatic patients
Time frame: At the point of recruitment
Willingness to receive support
Willingness to receive rehabilitation support for symptomatic patients
Time frame: At the point of recruitment
Health beliefs in relation to receiving rehabilitation support
Factors associated with the uptake of such sessions (using the HBM factors as well as sociodemographic factors of age, treatment status, social support, and highest education level)
Time frame: At the point of recruitment
Agreement on level of care
Agreement between patient and physician for the level of care they feel would be appropriate for their case (unsupervised exercise, supervised community-based rehabilitation, clinically-supervised rehabilitation, rehabilitation medicine consult, or exercise clearance/work-up). The professional judgement will be from a rehabilitation medicine physician with experience managing patients with cancer rehabilitation needs.
Time frame: At the point of recruitment
Plan to share: No — Data is protected under the SingHealth Data Protection Policy which is compliant to the Singapore Personal Data Protection Act 2012
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: start Jan 2025 → May 2026, primary completion Dec 2025 → Dec 2026 and completion Dec 2025 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.